NLS antibiotics

AstraZeneca is planning to move its antibiotic research and development business into a standalone company at a cost of about $40 million. The plan will affect about 95 people at its facility in Waltham, MA. The focus of the new company will be research and development of AstraZeneca’s early-stage antibiotic pipeline. This will include AZD0914, […]

According to a new register study in the scientific journal BMJ, researchers at Karolinska Institutet are able to dismiss previous claims that there is a link between the increased use of antibiotics in society and a coinciding rise in childhood asthma. The study includes half a million children and shows that exposure to antibiotics during pregnancy or […]

FOB Synthesis has entered into a research and development option and license agreement with AstraZeneca for the development of a novel antibiotic to treat drug-resistant bacterial infections. The treatment will potentially combine compounds from AstraZeneca’s preclinical beta lactamase inhibitor (BLI) and FOB Synthesis’ preclinical Carbapenem antibiotic programs to help break down bacteria’s resistance to carbapenems. […]

Nordic researchers are exploring bioactive compounds from the sea, looking for anticancer drugs, antibiotics, and more. The Baltic and North Seas contain more than great herring. The oceans also hold a wealth of biotechnology resources. So far, nine marine-inspired drugs such as the breast cancer therapy Halaven, have been approved in the United States or […]

A multimillion-euro partnership between industry and the European Union promotes research and communication on developing new antibiotics.